Article
Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70.
Department of Surgery, Teikyo University School of Medicine, Tokyo 173-0003, Japan.
Oncology Reports (impact factor:
1.84).
04/2009;
21(3):737-46.
Source: PubMed
-
Citations (0)
- Cited In (3)
-
Article: Cancer vaccine by fusions of dendritic and cancer cells.
[show abstract] [hide abstract]
ABSTRACT: Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells represents in many ways an ideal approach to deliver, process, and subsequently present a broad array of tumor-associated antigens, including those yet to be unidentified, in the context of DCs-derived costimulatory molecules. DCs/tumor fusion vaccine stimulates potent antitumor immunity in the animal tumor models. In the human studies, T cells stimulated by DC/tumor fusion cells are effective in lysis of tumor cells that are used as the fusion partner. In the clinical trials, clinical and immunological responses were observed in patients with advanced stage of malignant tumors after being vaccinated with DC/tumor fusion cells, although the antitumor effect is not as vigorous as in the animal tumor models. This review summarizes recent advances in concepts and techniques that are providing new impulses to DCs/tumor fusions-based cancer vaccination.Clinical and Developmental Immunology 01/2009; 2009:657369. · 1.84 Impact Factor -
Article: Regulation of tumor immunity by tumor/dendritic cell fusions.
[show abstract] [hide abstract]
ABSTRACT: The goal of cancer vaccines is to induce antitumor immunity that ultimately will reduce tumor burden in tumor environment. Several strategies involving dendritic cells- (DCs)- based vaccine incorporating different tumor-associated antigens to induce antitumor immune responses against tumors have been tested in clinical trials worldwide. Although DCs-based vaccine such as fusions of whole tumor cells and DCs has been proven to be clinically safe and is efficient to enhance antitumor immune responses for inducing effective immune response and for breaking T-cell tolerance to tumor-associated antigens (TAAs), only a limited success has occurred in clinical trials. This paper reviews tumor immune escape and current strategies employed in the field of tumor/DC fusions vaccine aimed at enhancing activation of TAAs-specific cytotoxic T cells in tumor microenvironment.Clinical and Developmental Immunology 01/2010; 2010:516768. · 1.84 Impact Factor -
Article: Role of heat shock protein 70 in innate alloimmunity.
[show abstract] [hide abstract]
ABSTRACT: This article briefly describes our own experience with the proven demonstration of heat shock protein 70 (HSP70) in reperfused renal allografts from brain-dead donors and reflects about its potential role as a typical damage-associated molecular pattern (DAMP) in the setting of innate alloimmunity. In fact, our group was able to demonstrate a dramatic up-regulation of HSP70 expression after postischemic reperfusion of renal allografts. Of note, up-regulation of this stress protein expression, although to a lesser extent, was already observed after cold storage of the organ indicating that this molecule is already induced in the stressed organism of a brain-dead donor. However, whether or not the dramatic up-regulation of HSP70 expression contributes to mounting an innate alloimmune response cannot be judged in view of these clinical findings. Nevertheless, HSP70, since generated in association with postischemic reperfusion-induced allograft injury, can be called a typical DAMP - as can every molecule be termed a DAMP that is generated in association with any stressful tissue injury regardless of its final positive or negative regulatory function within the innate immune response elicited by it. In fact, as we discuss in this article, the context-dependent, even contradistinctive activities of HSP70 reflect the biological phenomenon that, throughout evolution, mammals have developed an elaborate network of positive and negative regulatory mechanisms, which provide balance between defensive and protective measures against unwarranted destruction of the host. In this sense, up-regulated expression of HSP70 in an injured allograft might reflect a pure protective response against the severe oxidative injury of a reperfused donor organ. On the other hand, up-regulated expression of this stress protein in an injured allograft might reflect a (futile) attempt of the innate immune system to restore homeostasis with the aim to eliminate the "unwanted foreign allograft invader" by contributing to development of an adaptive alloimmune response. However, this adaptive immune response against donor histocompatibility alloantigens - in its evolutionary sense aimed to restore homeostasis - is by no means protective from a recipient's view point but tragically ends up with allograft rejection. Indeed: in this sense, allograft rejection is the result of a fateful confusion by the immune system of danger and benefit!Frontiers in immunology. 01/2011; 2:89.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
antigen presentation
CD8+ T cells
cells fusion
cross-present chaperoned antigenic peptides
CTL production
CTL productivity
dendritic cells
fusion cells
heat stress
heat-stressed tumor cells
HSP70 protein
MHC-restricted CTL production
multiple tumor antigens
paired autologous tumor cells
strong CTL productivity
tumor cells
tumor-associated CEA
unknown antigens
various loading methods
whole tumor cells